Liver Cancer Clinical Trial
Official title:
Impact of Portal Vein Embolization on Patient's Long-term Survival, Complications and Cancer Recurrence.
For patients with colorectal liver metastasis (CLM), the prospect of long-term survival
relies on liver resection. Wistfully, more than 75 % of patients with CLM are initially
unresectable, due to an insufficient future liver remnant (FLR) volume
In order to increase FLR volume, most patients will first receive chemotherapy to reduce the
tumor load (downsizing).
When chemotherapy is insufficient to provide an adequate postoperative FLR, portal vein
embolization (PVE) can be performed. About 50-70 % of patients undergoing PVE obtain a
sufficient liver hypertrophy to allow liver resection.
While PVE is recognised for its efficacy to induce liver hypertrophy, some studies expressed
substantial concerns regarding the potential adverse effect of this intervention on
pre-resection tumor progression, increased risk of cancer recurrence following resection and
reduced overall survival following resection
Those studies suggested that the need to perform PVE should be assessed thoroughly for each
patient and that chemotherapy should be maintained during the whole hypertrophy process in
order to contain the potential adverse effect of PVE on tumor progression.
Other studies found no significant association between PVE and negative oncological
outcomes.
As mentioned in almost every study cited above, more data is needed to provide a clearer
vision regarding the impact of PVE on tumor progression and cancer recurrence following
liver resection.
The aim of this study is to compare the overall and disease-free survival of PVE-requiring
patients to the ones who underwent upfront surgery (NoPVE).
As a secondary objective, the impact of several covariates (related to surgery, patient's
condition and disease stage) on survival and cancer recurrence will be tested.
Our hypothesis are that 1) PVE might be associated with a lower overall survival and a
higher risk of cancer recurrence in univariate analysis but 2) this association will not
remain significant when other covariates are included in the proportional COX hazard models.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03213314 -
HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies
|
N/A | |
| Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
| Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03756597 -
PAN-study: Pan-Cancer Early Detection Study (PAN)
|
||
| Recruiting |
NCT05160740 -
Indocyanine Green Molecular Fluorescence Imaging Technique Using in Diagnosis and Treatment of Primary Liver Cancer
|
N/A | |
| Completed |
NCT01906021 -
Study of New Software Used During Ablations
|
N/A | |
| Terminated |
NCT04589884 -
Intraoperative EXamination Using MAChine-learning-based HYperspectral for diagNosis & Autonomous Anatomy Assessment
|
||
| Recruiting |
NCT05953337 -
Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)
|
N/A | |
| Enrolling by invitation |
NCT04466124 -
Prospective Cohort Study of Liver Cancer Patients Treated With Proton Beam Therapy
|
||
| Not yet recruiting |
NCT04053231 -
Hepatocarcinoma Recurrence on the Liver Study - Part2
|
||
| Active, not recruiting |
NCT02869217 -
Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
|
Phase 1 | |
| Completed |
NCT03059238 -
Parecoxib Versus Celecoxib Versus Oxycodone in Pain Control for Transcatheter Chemoembolization Procedure
|
Phase 3 | |
| Recruiting |
NCT02632188 -
Radical Surgery Followed by Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen for the Treatment of Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT01388101 -
Real-time Diagnosis of Serum LECT 2 in Patient With Liver Cancer Using Electronic Antibody Sensor (e- Ab Sensor)
|
N/A | |
| Completed |
NCT01042041 -
Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer
|
Phase 1 | |
| Completed |
NCT00980239 -
HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver
|
Phase 1 | |
| Terminated |
NCT00903396 -
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
|
Phase 2 | |
| Completed |
NCT00790569 -
Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking
|
N/A | |
| Terminated |
NCT00896467 -
Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy
|
N/A | |
| Completed |
NCT00543777 -
Magnetic Resonance Elastography and 2-Point Dixon MR Imaging Techniques in Diffuse Liver Disease
|
Phase 1/Phase 2 |